Comparing labetalol and hydralazine for treating severe preeclampsia
The Effect of Intravenous Infusion of Labetalol Versus Hydralazine on Cerebral Hemodynamics of Preeclampsia Patients Prospective Randamized Study
This study tests whether labetalol or hydralazine is better at treating severe preeclampsia and improving brain health in pregnant women.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 25 Years to 45 Years |
| Sex | Female |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT06360601 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of intravenous labetalol compared to hydralazine in patients with severe preeclampsia, focusing on their impact on cerebral blood flow and neurological outcomes. The trial aims to determine which medication is more effective in managing this condition. It involves administering labetalol and hydralazine injections to eligible participants and monitoring their responses. The study is designed to provide insights into the optimal treatment for severe preeclampsia.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with severe preeclampsia.
Not a fit: Patients with a history of intracranial lesions, heart disease, or those allergic to the study drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols for severe preeclampsia, enhancing patient outcomes.
How similar studies have performed: While there have been studies on the treatment of preeclampsia, the specific comparison of labetalol and hydralazine in this context is less common, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient with clinical diagnosis of sever preeclampsia Exclusion Criteria: Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion -
Where this trial is running
Tanta
- Tanta Univeristy hospitals — Tanta, Egypt (Recruiting)
Study contacts
- Study coordinator: shimaa zahraa
- Email: Meikamal89@outlook.com
- Phone: 201550273707
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.